Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Rhea-AI Summary

Vera Therapeutics (NASDAQ: VERA), a late clinical-stage biotech company specializing in immunological disease treatments, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The event will be held in Miami Beach, FL from June 9-11, 2025. The company's management team will engage in a fireside chat scheduled for Wednesday, June 11, 2025, at 3:15pm EDT, and will also conduct one-on-one investor meetings. A webcast of the presentation will be available through the company's website, with replay access lasting 90 days in the "Investor Calendar" section.

BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami Beach, FL from June 9 – 11, 2025. The management team will also participate in one-on-one investor meetings.

Fireside Chat Details:
Date: Wednesday, June 11, 2025
Time: 3:15pm EDT
Webcast: https://cc.webcasts.com/gold006/060925a_js/?entity=165_UH4O74B

A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.

About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. For more information, please visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com

FAQ

When is Vera Therapeutics (VERA) presenting at the Goldman Sachs Healthcare Conference 2025?

Vera Therapeutics will present at the Goldman Sachs Healthcare Conference on Wednesday, June 11, 2025, at 3:15pm EDT in Miami Beach, FL.

Where can I watch Vera Therapeutics' (VERA) Goldman Sachs conference presentation?

The presentation can be accessed via webcast at https://cc.webcasts.com/gold006/060925a_js/?entity=165_UH4O74B and will be available for replay on Vera Therapeutics' website under the 'Investor Calendar' section for 90 days.

What type of meetings will Vera Therapeutics (VERA) conduct at the Goldman Sachs Healthcare Conference?

Vera Therapeutics' management team will participate in a fireside chat presentation and conduct one-on-one investor meetings during the conference.

What is Vera Therapeutics' (VERA) main business focus?

Vera Therapeutics is a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases.